Will AI Tools Like DocsGPT Drive the Next Leg of Growth for DOCS?

Doximity (DOCS) is leveraging AI tools like Doximity GPT to drive growth, reporting a 20% revenue increase, although the direct revenue impact of AI is not yet quantified. While DOCS's monetization remains heavily reliant on pharma marketing, AI is expected to enhance user engagement and potentially unlock new revenue streams, positioning the company for long-term diversification; DOCS's forward P/S ratio is 16.9X, higher than the industry average of 6X, and shares have gained 6.9% year-to-date, underperforming the industry's 28% growth.

Analysis

Doximity (DOCS) is strategically integrating artificial intelligence, exemplified by its Doximity GPT tool, which has contributed to a 20% top-line expansion and enhanced user engagement among clinicians. Despite strong adoption of these AI tools, management has not yet quantified their direct revenue impact, indicating that monetization is in an early, build-and-scale phase rather than being an immediate growth driver. The company's primary revenue source remains pharma marketing, an area susceptible to cyclical softness. AI is viewed as a long-term catalyst to bolster user stickiness, potentially opening future monetization avenues through premium subscriptions or value-added services, aiming for a growth rate roughly twice the market rate. However, DOCS shares have gained only 6.9% year-to-date, underperforming the industry's 28% growth. The stock trades at a high forward 12-month price-to-sales (P/S) ratio of 16.9X, significantly above the industry average of 6X and its own five-year median of 13.5X, and carries a Value Score of D. The Zacks Consensus Estimate for fiscal 2026 earnings per share suggests a modest 2.8% improvement from fiscal 2025. Competitors are also advancing in AI: Certara (CERT) reported an 18% year-over-year increase in software revenues to $46 million in Q1, largely driven by AI tool uptake, and authorized a $100 million share buyback. GE HealthCare (GEHC) saw Q1 2025 revenues grow nearly 4% organically to $4.78 billion and is heavily investing in AI across its portfolio, with plans to launch nearly 200 AI/ML-enabled devices in the next three years.

Key Decisions for Investors

• Investors should closely monitor Doximity's ability to translate strong AI tool adoption into quantifiable revenue streams, as this remains a key uncertainty despite the 20% overall revenue growth.
• Given DOCS's elevated P/S ratio of 16.9X, its significant year-to-date stock underperformance against the industry, and a Zacks Value Score of D, a cautious stance is advisable, awaiting clearer signals of AI monetization and improved valuation multiples.
• Consider the competitive AI advancements by peers such as Certara and GE HealthCare, which could impact Doximity's market differentiation and long-term growth prospects in the healthcare AI space.